Drug Trial Radar · NCT01358760
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Last checked: Nov 20, 2026Latest source record: Jun 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Jun 2011
Primary completion
Apr 2012
Study completion May 2012
Sponsor
- Lead sponsor
- EndoCeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- May 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.
Conditions
- Vaginal Atrophy
Interventions
PlaceboDrug
Placebo vaginal suppository
DHEADrug
Vaginal suppository containing 0.25% (3.25 mg) DHEA
DHEADrug
Vaginal suppository containing 0.5% (6.5 mg) DHEA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal SmearTime frame: Baseline and Week 12
- Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal SmearTime frame: Baseline and Week 12
- Change From Baseline to Week 12 in Vaginal pHTime frame: Baseline and Week 12
- Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal DrynessTime frame: Baseline and Week 12
Locations
42 sites in 2 countries. Site status is shown where the registry gives one.
EndoCeutics site # 39
Montgomery, Alabama
EndoCeutics site # 14
Tucson, Arizona
EndoCeutics site # 65
Little Rock, Arkansas
EndoCeutics site # 21
Sacramento, California
EndoCeutics site # 30
San Diego, California
EndoCeutics site # 36
Denver, Colorado
EndoCeutics site # 52
Denver, Colorado
EndoCeutics site # 66
Danbury, Connecticut
EndoCeutics site # 42
Milford, Connecticut
EndoCeutics site # 57
West Hartford, Connecticut
EndoCeutics site # 61
Newark, Delaware
EndoCeutics site # 26
Jacksonville, Florida
EndoCeutics site # 60
Lake Worth, Florida
EndoCeutics site # 54
North Miami, Florida
EndoCeutics site # 56
Pinellas Park, Florida
EndoCeutics site # 23
Sandy Springs, Georgia
EndoCeutics site # 10
Meridian, Idaho
EndoCeutics site # 55
Wichita, Kansas
EndoCeutics site # 27
Baltimore, Maryland
EndoCeutics site # 24
Omaha, Nebraska
EndoCeutics site # 50
Neptune City, New Jersey
EndoCeutics site # 33
Beachwood, Ohio
EndoCeutics site # 05
Cleveland, Ohio
EndoCeutics site # 47
Cleveland, Ohio
EndoCeutics site # 15
Columbus, Ohio
EndoCeutics site # 62
Providence, Rhode Island
EndoCeutics site # 64
Jackson, Tennessee
EndoCeutics site # 63
Memphis, Tennessee
EndoCeutics site # 53
San Antonio, Texas
EndoCeutics site # 51
Sandy City, Utah
EndoCeutics site # 09
West Jordan, Utah
EndoCeutics site # 03
Norfolk, Virginia
EndoCeutics site # 13
Calgary, Alberta, Canada
EndoCeutics site # 06
Bathurst, New Brunswick, Canada
EndoCeutics site # 59
Toronto, Ontario, Canada
EndoCeutics site # 04
Drummondville, Quebec, Canada
EndoCeutics site # 12
Montreal, Quebec, Canada
EndoCeutics site # 02
Québec, Quebec, Canada
EndoCeutics site # 01
Québec, Quebec, Canada
EndoCeutics site # 18
Saint Romuald, Quebec, Canada
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.